Stock COLL COLLEGIUM PHARMACEUTICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
36.42 USD +1.62% Intraday chart for Collegium Pharmaceutical, Inc. +4.54% +18.32%
04-11 Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes MT
02-26 Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
GL
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
GL
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes
MT
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
GL
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
AQ
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
GL
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
AQ
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating
MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating
MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase
MT
Collegium Pharmaceutical: Q4 Earnings Snapshot
AQ
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26
MT
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
GL
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
AQ
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
GL
Deadline Dexterity: PTAB Has Authority To Issue Decisions After Statutory Deadline
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COLL Stock
  4. News Collegium Pharmaceutical, Inc.